Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Gene Panel Differentiates Survival Outcomes in Humans Infected with Ebola

By LabMedica International staff writers
Posted on 31 Jan 2017
A team of molecular virologists used transcriptome data from individuals infected with Ebola virus and from convalescent patients recovering from the disease to identify early stage host factors that were associated with the acute illness and those that differentiated patients who survived from those that died.

The transcriptome is the set of all messenger RNA molecules in one cell or a population of cells. More...
It differs from the exome in that it includes only those RNA molecules found in a specified cell population, and usually includes the amount or concentration of each RNA molecule in addition to the molecular identities.

Investigators at the University of Liverpool used genomic techniques to identify and quantify messenger RNA (mRNA) expression in the blood of Ebola patients in Guinea who either went on to survive or die from the acute infection. These results were compared to blood samples from a separate group of survivors who had recovered from infection and were now free of the Ebola virus.

Results revealed that individuals who succumbed to the disease showed stronger upregulation of interferon signaling and acute phase responses compared to survivors during the acute phase of infection. Particularly notable was the strong upregulation of albumin and fibrinogen genes, which suggested significant liver pathology. Cell subtype prediction using messenger RNA expression patterns indicated that NK-cell populations increased in patients who survived infection.

Differences in immune cell populations predicted through analysis of gene expression patterns were validated on an independent group of Ebola virus patients using flow cytometry to directly measure the same cell types in patient blood. Machine learning was used to identify a panel of genes whose abundance could be used to predict the outcome of infection at the acute phase. This panel was validated on a separate independent group of patients with fatal or non-fatal outcome and whose viral loads were similar and was found to accurately predict outcome.

Senior author Dr. Julian Hiscox, professor of virology at the University of Liverpool, said, "Our study provides a benchmark of Ebola virus infection in humans and suggests that rapid analysis of a patient's response to infection in an outbreak could provide valuable predictive information on disease outcome."

The study was published in the January 19, 2017, online edition of the journal Genome Biology.


Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.